HeartSciences – MyoVista wavECG
MyoVista® Wavelet ECG (wavECGTM)
Breakthrough Technology for the Early Detection of Cardiac Dysfunction
MyoVista® Wavelet ECG (wavECG™) Testing Device is a new resting 12-lead electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. MyoVista wavECG Technology is designed to improve the sensitivity of an ECG in detecting ischemic and structural heart disease at an early stage. It’s patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on cardiac performance and energy during repolarization rather than conventional voltage-based ECG information and provide valuable new data to assist in identifying repolarization abnormalities.
About MyoVista
MyoVista wavECG Analysis Results Indicator and Risk Score
The MyoVista wavECG Result Indicator and LV Relaxation Risk Score are calculated using MyoVista AI-based algorithms that incorporate data from the transformed ECG signal using continuous wavelet signal processing.
The MyoVista wavECG Result Indicator categorizes the overall wavECG Analysis as either “Normal”, “Borderline”, or “Abnormal” for risk of abnormal LV relaxation.
The MyoVista LV Relaxation Risk Score is provided on a scale from 1-6. Patients having a risk score of 1 and 2 are not detected to have an elevated risk and patients with a risk score of 5 and 6 have substantially elevated risk for abnormal LV relaxation. The categorization of “Normal”, “Borderline” or “Abnormal” is determined by the Risk Score which is located just below the MyoVista wavECG Result Indicators.
Intuitive Touch Screen Interface
The MyoVista wavECG Device features a high definition (1920 x 1080) touch screen incorporating many easy and intuitive features commonly associated with a tablet device. The MyoVista Device displays the proprietary wavECG Information as well as the conventional waveforms, information and interpretive analysis you would expect from a full-featured ECG. The MyoVista wavECG Device follows the conventional AHA/IEC resting 12-lead placement protocols.
MyoVista wavECG Information
The MyoVista wavECG Device provides information related to patient risk for abnormal LV relaxation and may be used by a physician as part of an overall risk assessment to assist in determining if a patient should receive further clinical testing, evaluation and/or treatment.
The MyoVista wavECG Device’s analysis of LV relaxation has been developed to correlate to echocardiographic e-prime (e’). Measurements of septal e’ <7 cm/s or lateral e’ <10 cm/s are considered abnormal per the ASE/AECVI guidelines for the evaluation of LV diastolic function using echocardiography. HeartSciences recommends that the MyoVista wavECG Information be used in conjunction with other health-related patient information to determine the appropriate clinical care pathway and treatment options for each patient.
Conventional ECG Trace with Interpretive Analysis
The MyoVista wavECG Device provides conventional ECG trace information as well as the University of Glasgow 12-lead ECG Interpretive Analysis Algorithm that has more than 35 years of history and is considered one of the world’s leading ECG interpretive algorithms in the world.